Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2012

View Archived Issues

Dalcetrapib continues to show positive effects on HDL cholesterol

Characterization of new ApoA-I formulation presented at different meetings

Aeterna Zentaris presents promising compound for cancer treatment

Astellas Pharma discloses new phosphodiesterase 9A inhibitors

New EthR inhibitor enhances antimycobacterial activity of ethionamide

Discovery and entry of ABT-199 into clinic reported at AACR meeting

University of Pittsburgh synthesizes new p53/Mdm2 antagonists

Novel microRNA-based tests classify tumor types with high accuracy

LabCorp licenses diagnostic technology for Alzheimer's disease

FDA extends review of Lymphoseek

GTx replies to FDA's clinical hold letter regarding Capesaris

Fresenius Medical Care gains marketing rights to TRK-820

Genzyme submits mipomersen NDA in U.S.

BLA submission completed for metreleptin

New recombinant therapy enters phase I trial in coronary artery disease

Xencor receives milestone payment from Boehringer Ingelheim

Hanmi Pharmaceutical's HM-47000 selected as a government project

Preclinical development of antibiotic completed

Sclerostin-directed antibody advances to phase III for osteoporosis

Shin Nippon Biomedical reports phase I data on intranasal zolmitriptan

New metabotropic glutamate mGlu5 receptor modulators designed

Novel BTK inhibitors reported

Takeda presents novel cognition-enhancing products

Trillium provides update on lead cancer program

FDA grants priority review to Zaltrap BLA

Mercury Pharma combination therapy approved in Scotland

Newron and Zambon provide update on safinamide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...